Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel, Phase III Study to Evaluate the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia Disorder

NCT07028697 is registered in ClinicalTrials.gov with Nxera Pharma Korea Co., Ltd. as lead sponsor.

NCT NCT07028697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07028697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel, Phase III Study to Evaluate the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia Disorder
Lead sponsor
Nxera Pharma Korea Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
December 4, 2024
Completion date
October 21, 2025
Enrollment
164 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

insomnia disorder